ArticleCureus2026
Expression of PTEN and p53 and Their Clinicopathological Correlation in Breast Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is one of the most common malignancies in women and is a major cause of cancer-related mortality. Alterations in the expression of tumor suppressor genes such as PTEN and p53 may influence tumor behavior and prognosis. This study aimed to evaluate the immunohistochemical expression of PTEN and p53 in breast carcinoma and analyze their association with clinicopathological parameters.
methodsA cross-sectional study was conducted on 50 histologically confirmed female breast carcinoma cases. Immunohistochemistry (IHC) for PTEN and p53 was performed using standard protocols. PTEN expression was assessed based on cytoplasmic and nuclear staining intensity and categorized as positive or negative. p53 expression was evaluated as nuclear positivity and categorized similarly. Statistical analysis was done using standard significance tests.
resultsThe mean patient age was 49.8 years. The most common histologic subtype was infiltrating ductal carcinoma (IDC). Loss of PTEN expression was found in most of the cases and was associated with higher tumor grade and lymph node metastasis. Most cases exhibited p53 overexpression, which showed trends toward an association with higher tumor grade, premenopausal status, and lymph node positivity. An inverse relationship was noted between PTEN loss and p53 positivity.
conclusionsPTEN loss and p53 overexpression were frequent in breast carcinoma and correlated with aggressive tumor features. Combined assessment of these biomarkers may provide prognostic value and support therapeutic decision-making in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.